INTERVIEW

Taiyo Pharma Eyeing 10 Trillion Yen Japanese Market, Looking to Use In-House Technologies to Develop New Products: COO

January 10, 2018
The Taiyo Group, which is mainly involved in the manufacture and sale of chemicals for use in the electronics industries, entered the pharmaceutical industry by establishing Taiyo Pharma in August 2017. The company will initially market long-listed products (LLPs) acquired…

To read the full story

Related Article

INTERVIEW

By Shinya Sato

As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…

Takeda Pharmaceutical completed the £46 billion acquisition of Shire on January 8, vaulting itself into the top 10 league of…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…